Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Tax Provisions: 2023-2025

Historic Tax Provisions for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to -$2.4 million.

  • Iovance Biotherapeutics' Tax Provisions fell 58.22% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$671,000, marking a year-over-year increase of 89.19%. This contributed to the annual value of -$2.8 million for FY2024, which is 19.20% up from last year.
  • Iovance Biotherapeutics' Tax Provisions amounted to -$2.4 million in Q3 2025, which was down 220.25% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Tax Provisions registered a high of $2.0 million during Q2 2025, and its lowest value of -$2.4 million during Q3 2025.
  • For the 3-year period, Iovance Biotherapeutics' Tax Provisions averaged around -$862,200, with its median value being -$1.5 million (2024).
  • Per our database at Business Quant, Iovance Biotherapeutics' Tax Provisions slumped by 200.00% in 2024 and then surged by 233.33% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Tax Provisions (Quarterly) stood at -$1.8 million in 2023, then spiked by 188.31% to $1.6 million in 2024, then slumped by 58.22% to -$2.4 million in 2025.
  • Its Tax Provisions was -$2.4 million in Q3 2025, compared to $2.0 million in Q2 2025 and -$1.8 million in Q1 2025.